Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.

Abstract

BACKGROUND:

TT-232, a somatostatin analogue, induces apoptosis in various tumours. The aim of our study was to characterise its effect on human melanoma cells and tumours.

MATERIALS AND METHODS:

Proliferation of seven melanoma cell lines was tested in vitro with the methylene blue test. D10 and 205 cells were also implanted into CB17-scid mice which received 30-150-750 micrograms/kg/day of TT-232 or saline. Animals with 205 cells received twice-daily subcutaneous injections whereas animals with D10 cells were treated with osmotic mini-pumps. In addition, TT-232 metabolites were generated with tissue homogenates and tested in vitro.

RESULTS:

TT-232 strongly inhibited proliferation of all cell lines in vitro and tumour growth in vivo. Two out of 8 animals (30-150 micrograms/kg) in the 205 model and one out of 8(150 micrograms/kg) in the D10 model became completely tumour-free at the 11th and 9th day of treatment, respectively. TT-232 was degraded only by liver homogenate whilst its metabolite had no antiproliferative effect in vitro.

CONCLUSIONS:

TT-232 is a promising drug candidate for melanoma.

• Authors: R E Schwab, S Froidevaux, S Paku, M Tejeda, B Szende, A Pap, C Beglinger, A N Eberle, G Kéri
• Journal: Anticancer research (Anticancer Res) 2001 Jan-Feb Vol. 21 Issue 1A Pg. 71-5 ISSN: 0250-7005 [Print] Greece
• PMID: 11299792 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Peptides, Cyclic
• TT2-32
• Somatostatin

Topics

• Animals
• Antineoplastic Agents (pharmacokinetics, pharmacology, therapeutic use)
• Cell Division (drug effects)
• Chromatography, High Pressure Liquid
• Drug Screening Assays, Antitumor
• Female
• Humans
• Melanoma (drug therapy, pathology)
• Mice
• Mice, SCID
• Peptides, Cyclic (pharmacokinetics, pharmacology, therapeutic use)
• Somatostatin (analogs & derivatives)
• Tumor Cells, Cultured